Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
178 hedge funds and large institutions have $2.13B invested in Intra-Cellular Therapies Inc. in 2020 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 60 increasing their positions, 51 reducing their positions, and 38 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
41% more call options, than puts
Call options by funds: $30.1M | Put options by funds: $21.3M
35% more capital invested
Capital invested by funds: $1.58B → $2.13B (+$548M)
18% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 51
1% more funds holding
Funds holding: 176 → 178 (+2)
8% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 38
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$24.3M |
| 2 |
BlackRock
New York
|
+$16.5M |
| 3 |
Goldman Sachs
New York
|
+$12M |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$10.9M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$9.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$14.3M |
| 2 |
Millennium Management
New York
|
-$10.6M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$9.73M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$8.88M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.41M |
ITCI Hedge Fund Activity: Q4 2020 in Review
178 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q4 2020, worth a combined $2.13B — up 35% from $1.58B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new ITCI positions and 38 closed out — a net gain of 3 holders — while 60 added to existing stakes and 51 trimmed.
The largest buyer was Wasatch Advisors, adding an estimated $24.3M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $14.3M sold.
- 178 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q4 2020, up from 176 in Q3 2020.
- Funds reported $2.13B of Intra-Cellular Therapies Inc. stock for Q4 2020, up 35% quarter-over-quarter.
- 41 funds opened new Intra-Cellular Therapies Inc. positions in Q4 2020 and 38 closed out, a net change of +3 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q4 2020 was Wasatch Advisors, an estimated $24.3M added.
- The largest Intra-Cellular Therapies Inc. seller in Q4 2020 was Point72 Asset Management, an estimated $14.3M sold.
Based on aggregated 13F filings for Q4 2020.